ProfoundBio takeout shines a light on Sutro
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
A roundup of the first quarter's key oncology drug approvals and rejections.
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.
Imetelstat appears headed for approval after its US adcom turns into a damp squib.
The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.
Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.